search
Back to results

Effect of KETOgenic Diet on Metabolism, Inflammation, Nutrition Deficiencies and OXidative Stress in Women With Overweight (KETO-MINOX)

Primary Purpose

Overweight and Obesity

Status
Active
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Ketogenic diet
Control diet
Sponsored by
Polish Academy of Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Overweight and Obesity focused on measuring diet, nutrition, ketogenic diet, inflammation, oxidative stress, overweight

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: women age 18-45 overweight (BMI 27 - 35) motivation to lose weight and participate in the nutritional intervention trial Exclusion Criteria: overweight/obesity secondary to genetic syndromes endocrine diseases, acute systemic disease, autoimmune disorders pregnancy breastfeeding type 1 and 2 diabetes any other chronic diseases requiring pharmacotherapy (including topical steroids in allergy disorders supplement or medication use influencing appetite, weight or metabolism) participation in other clinical trials severe obesity (BMI > 35) > 3 kg weight loss 12 weeks before the initial test day extreme changes in exercise intensity 4 weeks prior any diagnosed psychiatric disorders

Sites / Locations

  • Department of Family Medicine and Infectious Diseases, Faculty of Medical Sciences, University of Warmia and Mazury
  • Institute of Animal Reproduction and Food Research, Polish Academy of Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Ketogenic diet

Control diet

Arm Description

40 women which will follow the ketogenic diet with 1700 kcal daily for 8 weeks

40 women which will follow the standard diet with 1700 kcal daily for 8 weeks

Outcomes

Primary Outcome Measures

Inflammatory markers (G-CSF, GM-CSF, INF-gamma, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, MCP-1, MIP-1b, TNF-a)
Analysis using Bio-Plex Pro™ Human Cytokine 17-plex Assay in serum.
Oxidative stress markers
analysis of malondialdehyde, superoxide dismutase, 8-isoprostane and 8-hydroxydeoxyguanosine (8-OHdG) using commercial ELISA kits in serum.

Secondary Outcome Measures

Body weight and composition
Body weight in kg and composition in % will be measured using Body Composition Analyser
Waist circumference
The waist circumference in cm will be measured using a standard measurement tape.
Free amino acids
Analysis of free amino acids in serum using gas chromatography-mass spectrometry, expressed in nmol/mL
Fat-soluble vitamins
Fat-soluble vitamins in serum using commercial ELISA kits (vitamin D) and high-performance liquid chromatography (vitamin A,E & K)
Metabolites in breath
Volatile organic compounds in breath will be measured using dwo dimensional chromatography with time of flight mass spectrometry (GCxGC-ToFMS)
Obesity-related markers (C-peptide, ghrelin, gastric inhibitory peptide (GIP), glucagon-like peptide 1 (GLP-1), glucagon, insulin, leptin, plasminogen activation inhibitor-1 (PAI-1), resistin and visfatin, adipsin and adiponectin)
Analyses will be performed using Bio-Plex Assays

Full Information

First Posted
November 29, 2022
Last Updated
May 9, 2023
Sponsor
Polish Academy of Sciences
Collaborators
University of Warmia and Mazury
search

1. Study Identification

Unique Protocol Identification Number
NCT05652972
Brief Title
Effect of KETOgenic Diet on Metabolism, Inflammation, Nutrition Deficiencies and OXidative Stress in Women With Overweight
Acronym
KETO-MINOX
Official Title
KETO-MINOX: The Effect of Isocaloric, Energy-restrictive, KETOgenic Diet on Metabolism, Inflammation, Nutrition Deficiencies and OXidative Stress in Women With Overweight and Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 1, 2023 (Actual)
Primary Completion Date
May 30, 2024 (Anticipated)
Study Completion Date
February 28, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Polish Academy of Sciences
Collaborators
University of Warmia and Mazury

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In recent times, the prevalence of obesity increases, reaching an epidemic scale. Elevated body weight is a risk factor in the development of several diseases such as diabetes, hypertension and cancer. Therefore, obesity management solutions, such as diet therapy are needed. The key issue is to choose the most appropriate diet to obtain an efficient outcome in losing weight, without experiencing adverse effects and a decrease in general health. A ketogenic diet, an auxiliary therapy for epilepsy, is recently one of the options commonly used for losing weight by overweight individuals, tempted by the commercials and internet influencers. However, there is limited knowledge about the effect of this diet on human health. To date, the majority of studies were conducted with a very-low-calorie regime applied before the bariatric surgeries, which itself may affect the loss of body weight, and in most studies, the control diets were missing. Taking into consideration that a ketogenic diet is an extremely eliminating diet, there is a risk of nutritional deficiencies after following it. Therefore, there is a strong need for more in-depth and comprehensive elucidation of the safety and physiological effects of the ketogenic diet used for the weight loss in overweight and obese individuals. This Project aims to evaluate the effectiveness of the eight-week, isocaloric, energy-restricted, ketogenic diet as a weight management solution in women with overweight and obesity compared to the standard, balanced diet with the same calorie content.
Detailed Description
In recent times, the prevalence of obesity increases, reaching an epidemic scale. A new factor supporting a weight gain is a current coronaviros (COVID-19) pandemic, associated with reduced physical activity, high stress and overeating, which resulted in 2-5 kg weight gain in 20 % of the American population within a few months 1. Elevated body weight is a risk factor in developing several diseases such as diabetes, hypertension and cancer. Therefore, obesity management solutions, such as diet therapy, are needed. The critical issue is to choose the most appropriate diet to obtain an efficient outcome in losing weight without experiencing adverse effects and a decrease in general health. A ketogenic diet, an auxiliary therapy for epilepsy, is recently one of the options commonly used for losing weight by individuals with overweight, tempted by the commercials and internet influencers. However, there is limited knowledge about the effect of this diet on human health. To date, the majority of studies were conducted with a very low-calorie regime applied before the bariatric surgeries, which itself may affect the loss of body weight. In most studies, the control diets were missing. Considering that a ketogenic diet is an extremely eliminating diet, there is a risk of nutritional deficiencies after following it. Therefore, there is a strong need for more in-depth and comprehensive elucidation of the safety and physiological effects of the energy-restricted ketogenic diet used for weight loss in individuals with overweight and obese. This Project aims to evaluate the effectiveness of the eight-week, isocaloric, energy-restricted, ketogenic diet as a weight management solution in women with overweight and obesity compared to the standard, balanced diet with the same calorie content.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight and Obesity
Keywords
diet, nutrition, ketogenic diet, inflammation, oxidative stress, overweight

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ketogenic diet
Arm Type
Experimental
Arm Description
40 women which will follow the ketogenic diet with 1700 kcal daily for 8 weeks
Arm Title
Control diet
Arm Type
Active Comparator
Arm Description
40 women which will follow the standard diet with 1700 kcal daily for 8 weeks
Intervention Type
Other
Intervention Name(s)
Ketogenic diet
Intervention Description
1700 kcal ketogenic diet (fat: protein: carbohydrate ratio of 70:20:10)
Intervention Type
Other
Intervention Name(s)
Control diet
Intervention Description
1700 kcal standard diet (fat: protein: carbohydrate ratio of 20:30:50)
Primary Outcome Measure Information:
Title
Inflammatory markers (G-CSF, GM-CSF, INF-gamma, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, MCP-1, MIP-1b, TNF-a)
Description
Analysis using Bio-Plex Pro™ Human Cytokine 17-plex Assay in serum.
Time Frame
12 months
Title
Oxidative stress markers
Description
analysis of malondialdehyde, superoxide dismutase, 8-isoprostane and 8-hydroxydeoxyguanosine (8-OHdG) using commercial ELISA kits in serum.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Body weight and composition
Description
Body weight in kg and composition in % will be measured using Body Composition Analyser
Time Frame
12 months
Title
Waist circumference
Description
The waist circumference in cm will be measured using a standard measurement tape.
Time Frame
12 months
Title
Free amino acids
Description
Analysis of free amino acids in serum using gas chromatography-mass spectrometry, expressed in nmol/mL
Time Frame
12 months
Title
Fat-soluble vitamins
Description
Fat-soluble vitamins in serum using commercial ELISA kits (vitamin D) and high-performance liquid chromatography (vitamin A,E & K)
Time Frame
12 months
Title
Metabolites in breath
Description
Volatile organic compounds in breath will be measured using dwo dimensional chromatography with time of flight mass spectrometry (GCxGC-ToFMS)
Time Frame
12 months
Title
Obesity-related markers (C-peptide, ghrelin, gastric inhibitory peptide (GIP), glucagon-like peptide 1 (GLP-1), glucagon, insulin, leptin, plasminogen activation inhibitor-1 (PAI-1), resistin and visfatin, adipsin and adiponectin)
Description
Analyses will be performed using Bio-Plex Assays
Time Frame
12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: women age 18-45 overweight (BMI 27 - 35) motivation to lose weight and participate in the nutritional intervention trial Exclusion Criteria: overweight/obesity secondary to genetic syndromes endocrine diseases, acute systemic disease, autoimmune disorders pregnancy breastfeeding type 1 and 2 diabetes any other chronic diseases requiring pharmacotherapy (including topical steroids in allergy disorders supplement or medication use influencing appetite, weight or metabolism) participation in other clinical trials severe obesity (BMI > 35) > 3 kg weight loss 12 weeks before the initial test day extreme changes in exercise intensity 4 weeks prior any diagnosed psychiatric disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Natalia Drabińska, PhD
Organizational Affiliation
Institute of Animal Reproduction and Food Reseach, Polish Academy of Sciences in Olsztyn
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jerzy Romaszko, MD, PhD
Organizational Affiliation
Deaprtment of Family Medicine and Infectious Diseases, Faculty of Medical Sciences, University of Warmia and Mazury
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Family Medicine and Infectious Diseases, Faculty of Medical Sciences, University of Warmia and Mazury
City
Olsztyn
ZIP/Postal Code
10-082
Country
Poland
Facility Name
Institute of Animal Reproduction and Food Research, Polish Academy of Sciences
City
Olsztyn
ZIP/Postal Code
10-748
Country
Poland

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
During the project only new data will be acquired and/or generated. No existing data re-usage is planned. Similar data do not exist yet, thus the planned project will be the only source/origin of them. In the project the following data will be generated: numerical data, texts and graphical data (chromatography). During the the project, two types of data will be generated to further processing: automatic measurement data resulting from the equipment, obtained using the validated methodologies and calibrated equipments with the predefined replicates. non-automatic measurement data resulting from carried out experiments - data documented manually and then entered into a spreadsheets and obtained after the statistical evaluation. All data will be successfully published in prestigious journals with high Impact Factor. Thus, they will be evaluated by the expert reviewers in the process of revision.

Learn more about this trial

Effect of KETOgenic Diet on Metabolism, Inflammation, Nutrition Deficiencies and OXidative Stress in Women With Overweight

We'll reach out to this number within 24 hrs